Market Closed -
OTC Markets
03:55:07 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
0.0821
USD
|
+0.07%
|
|
+2.62%
|
+12.47%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
110.6
|
34.54
|
24.94
|
31
|
10.5
|
9.014
|
Enterprise Value (EV)
1 |
110.2
|
34.84
|
25.09
|
31.64
|
10.93
|
8.892
|
P/E ratio
|
-3.7
x
|
-1.25
x
|
-6.07
x
|
-10.7
x
|
-6.79
x
|
-286
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-3.95
x
|
-1.28
x
|
-6.38
x
|
-11.8
x
|
-7.5
x
|
-12.4
x
|
EV / FCF
|
16.3
x
|
4.09
x
|
20.9
x
|
151
x
|
-39.8
x
|
-14.9
x
|
FCF Yield
|
6.14%
|
24.4%
|
4.78%
|
0.66%
|
-2.52%
|
-6.7%
|
Price to Book
|
40.3
x
|
29
x
|
28.3
x
|
50.2
x
|
61.8
x
|
35.3
x
|
Nbr of stocks (in thousands)
|
105,361
|
108,323
|
113,373
|
119,223
|
123,483
|
123,483
|
Reference price
2 |
1.050
|
0.3189
|
0.2200
|
0.2600
|
0.0850
|
0.0730
|
Announcement Date
|
4/16/19
|
3/30/20
|
3/31/21
|
3/31/22
|
3/31/23
|
4/1/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-27.9
|
-27.26
|
-3.931
|
-2.672
|
-1.458
|
-0.7182
|
EBIT
1 |
-28.08
|
-27.42
|
-4.076
|
-2.801
|
-1.569
|
-0.7706
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-29.32
|
-27.53
|
-4.065
|
-2.842
|
-1.528
|
-0.0306
|
Net income
1 |
-29.32
|
-27.53
|
-4.065
|
-2.842
|
-1.528
|
-0.0316
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2841
|
-0.2557
|
-0.0362
|
-0.0243
|
-0.0125
|
-0.000255
|
Free Cash Flow
1 |
6.772
|
8.516
|
1.199
|
0.2101
|
-0.2751
|
-0.5956
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/19
|
3/30/20
|
3/31/21
|
3/31/22
|
3/31/23
|
4/1/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.3
|
0.15
|
0.64
|
0.44
|
-
|
Net Cash position
1 |
0.41
|
-
|
-
|
-
|
-
|
0.12
|
Leverage (Debt/EBITDA)
|
-
|
-0.0109
x
|
-0.0378
x
|
-0.2404
x
|
-0.3008
x
|
-
|
Free Cash Flow
1 |
6.77
|
8.52
|
1.2
|
0.21
|
-0.28
|
-0.6
|
ROE (net income / shareholders' equity)
|
-1,878%
|
-1,390%
|
-391%
|
-379%
|
-388%
|
-14.8%
|
ROA (Net income/ Total Assets)
|
-811%
|
-689%
|
-135%
|
-92.7%
|
-54.6%
|
-38%
|
Assets
1 |
3.615
|
3.995
|
3.009
|
3.066
|
2.799
|
0.0831
|
Book Value Per Share
2 |
0.0300
|
0.0100
|
0.0100
|
0.0100
|
0
|
0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
1 |
0.83
|
0
|
-
|
0.27
|
-
|
0.01
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/19
|
3/30/20
|
3/31/21
|
3/31/22
|
3/31/23
|
4/1/24
|
|
1st Jan change
|
Capi.
|
---|
| +12.47% | 10.13M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|